Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Recently, anti–programmed cell death protein 1 drugs have shown durable response in melanoma, non–small-cell lung cancers, and renal cell cancers.1,2 The article “Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression” by Sanlorenzo et al3 describes interesting clinical findings, yet we have the following comments regarding the statistical analyses.
Hwang SJE, Byth K, Fernandez-Penas P. Time-Dependent Measurement of Adverse Events. JAMA Dermatol. 2015;151(12):1392. doi:10.1001/jamadermatol.2015.3579
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: